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Anemia as a risk factor for cardiovascular disease. In the pres-
ent review we examine the physiologic response to chronic
anemia and describe potential adverse effects of anemia on
myocardial and large arterial remodeling. We present observa-
tional data demonstrating that anemia is a risk factor for cardio-
vascular disease (CVD) outcomes in patients with chronic kid-
ney disease and patients with heart failure. We also present
data that have evaluated the relationship of level of hematocrit
to CVD outcomes in patients with ischemic heart disease and
in patients in the general population. The results from the
latter studies have been inconclusive and have been limited by
lack of knowledge of the cause of anemia. This is potentially
important because iron deficiency anemia may, in fact, improve
endothelial function. We conclude that additional randomized
controlled trials of treatment of anemia are needed in chronic
kidney disease and patients with heart failure; however, further
exploration of the cause of anemia and the effect of different
types of anemia on various CVD outcomes are needed in
patients with ischemic heart disease and patients in the general
population.
Chronic anemia may have adverse effects on myocar-
dial and large arterial remodeling. Decreased iron stores
and, therefore, potentially, iron deficiency anemia may,
however, improve endothelial function and thereby de-
crease cardiovascular disease (CVD) outcomes. In this
review we discuss observational and controlled trials that
have evaluated the effect and treatment of chronic ane-
mia on CVD outcomes in 3 populations: patients with
chronic kidney disease (CKD); patients with CVD; and
subjects in the general population. We choose not to
focus on the relationship of anemia to outcomes in sub-
jects who are undergoing surgery, patients with malig-
nancy, and patients in the intensive care unit as this is
beyond the scope of the current article.
PATHOPHYSIOLOGY: POTENTIAL ADVERSE
EFFECTS OF CHRONIC ANEMIA ON THE
HEART AND BLOOD VESSELS
Effects of anemia on the myocardium
Although the exact role of anemia in promoting CVD
is currently not well understood, maintenance of ade-
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quate tissue oxygenation in the anemic state is achieved
by both non-hemodynamic and hemodynamic adapta-
tions. Non-hemodynamic adaptations include increases
in erythropoietin production and increases in intra-eryth-
rocytic concentrations of 2,3-diphosphoglycerate [1]. He-
modynamic changes include systemic arterial dilatation,
which leads to a decreased systemic vascular resistance,
and reduced afterload, which in turn may increase stroke
volume [2]. Anemia also results in decreased blood vis-
cosity, which increases venous return and thus, augments
preload. Finally, the presence of anemia activates the
sympathetic nervous system, which results in an increase
in heart rate [3]. Increased preload, heart rate, and stroke
volume, as well as reduced afterload all act to raise car-
diac output.
Over the long term, adaptations that initially increase
cardiac output may lead to left ventricular enlargement
and eccentric left ventricular hypertrophy (LVH), char-
acterized by increased LV internal dimensions and a
normal ratio of wall thickness to cavity diameter (Fig.
1). The latter is well appreciated in patients with sickle
cell disease [4], as well as in patients who are anemic
secondary to their CKD [5]. Patients with CKD also
have a high prevalence of comorbid conditions such as
hyperparathyroidism and a high calcium/phosphorus
product, which may contribute to myocardial fibrosis and
calcium deposition. In this setting, the effects of anemia
on myocardial remodeling may be aggravated, resulting
in more severe LVH and less reversible pathology [6].
Left ventricular hypertrophy, in turn, may predispose to
heart failure or aggravate ischemic heart disease (IHD).
It remains unknown whether more subtle changes in
cardiac remodeling may occur in patients with less severe
degrees of anemia and in patients with other causes of
anemia.
Effects of anemia on the blood vessel wall
Chronic anemia may also adversely affect large blood
vessels, resulting in arterial hypertrophy and remodeling,
occurring as a result of sustained increases in cardiac
output [7, 8]. In theory, this may reverse the early vasodi-
latation characteristic of anemia and lead to increased
systemic vascular resistance, which further contributes
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Fig. 1. Schematic relationship of left ventricular (LV) mass and hema-
tocrit (Hct) in the general population. The U-shaped curve indicates
an increase of cardiac mass with both anemia and polycythemia, albeit
due to different mechanisms (upper panel). Reproduced with permis-
sion from reference [51].
to the development of LVH. Early on, these changes
may be reversible; however, in conditions such as CKD,
they may become permanent [6].
Effects of anemia on precipitating ischemia in subjects
with prevalent CVD
It has been shown that the resting human heart can
withstand acute severe isovolemic anemia as low as 5.0
g/dL, without evidence of inadequate systemic oxygen-
ation. Acute isovolemic hemoglobin reduction to 5.0
g/dL in 33 healthy resting subjects produced no evidence
of hypoxia, assessed by change in oxygen consumption
or an increase in plasma lactate concentration [9]. Analy-
sis of Holter readings suggests that at this level of hemo-
globin concentration in the resting healthy population,
myocardial ischemia would occur only infrequently [9].
However, animal experiments and studies in postopera-
tive patients with CVD suggest that the presence of IHD
may significantly impair the heart’s ability to tolerate
low levels of hemoglobin [10, 11].
OTHER REASONS WHY ANEMIA MAY BE
ASSOCIATED WITH CVD OUTCOMES
It is important to recognize that, although studies may
demonstrate an association between anemia and CVD
outcomes, this does not necessarily imply that anemia is
the cause and, therefore, a treatable cause of CVD. That
is, confounding from unmeasured factors, or residual
confounding from measured factors may be playing a
role. Two examples include the following: (1) anemia
may be associated with an unmeasured risk factor, such
as inflammatory status, which in turn is the cause of both
the anemia and the causal risk factor associated with
CVD; and (2) anemia may be a marker of the severity
of underlying heart disease. For example, in patients
with heart failure, anemia may be due to hemodilution
associated with the severity of heart failure [12].
DOES THE CAUSE OF ANEMIA AFFECT CVD
RISK? A POTENTIAL PROTECTIVE EFFECT
OF IRON DEFICIENCY
In 1981, Sullivan [13] proposed that iron depletion
and, by inference, potentially iron deficiency anemia may
protect against IHD. Although controversial, there have
been several lines of support for this hypothesis.
Different rates of IHD incidence in men and women
The crude IHD death rate in United States men and
women aged 35 to 74 is 219 and 91 per 100,000 popula-
tion, respectively [14]. The incidence of IHD is consis-
tently higher in men of all age groups compared to
women in the same age groups, with the maximal differ-
ence of 300% in the 45 to 54 age group.
The difference in the incidence of IHD appears to
parallel the changes in iron stores seen with increasing
age. In men, iron stores, assessed by serum ferritin con-
centration, rise after adolescence [15]. In women, iron
stores remain low and only begin to rise after the age
of 45 years [16]. The maximal sex difference in serum
ferritin level is reached at approximately 45 years of age
[17].
Why iron deficiency may be protective
Redox-active iron may contribute to lipid peroxida-
tion, endothelial cell activation, and generation of reac-
tive oxygen species [18]. Increased oxidative stress, in
turn, may be associated with impaired action of endothe-
lium-derived nitric oxide in patients with atherosclerosis,
thus contributing to endothelial dysfunction [19]. Iron
chelation has been shown to improve endothelial func-
tion in patients with coronary artery disease, supporting
the theory that iron may damage the endothelium [20].
Observational studies linking iron stores to IHD
Some [21], but not all [22] studies have noted an associ-
ation between increased iron stores and risk of IHD.
For example, a study of 9920 Canadian men and women
demonstrated an association between levels of serum
iron and risk of fatal acute myocardial infarction. The
rate ratio in the highest category of serum iron levels
compared to the lowest category was 2.18 for men and
5.53 for women, respectively [21].
Studies from the Framingham population have also
been consistent with the iron hypothesis [23]. That is,
the risk of IHD in women increased equally by natural
menopause or by surgical menopause (independent of
oophorectomy). Thus, uterine factors, rather than hor-
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monal factors, might be responsible for the protection
of premenopausal women against IHD.
Blood donation may reduce IHD risk
If iron deficiency was protective, one could hypothe-
size that frequent donation of blood may reduce IHD.
In fact, in a prospective cohort of 2682 Finnish men
followed for up to 5.5 years, blood donation was shown
to decrease the risk of myocardial infarction by 86%
[24]. This finding, however, has not been consistent. For
example, although 655 blood donors had half the risk of
CVD events compared to 3200 non-donors in an unad-
justed analysis, this difference was no longer significant
after adjustment for potential confounders [25].
OVSERVATIONAL STUDIES AND
INTERVENTIONAL TRIALS RELATING
ANEMIA TO CVD OUTCOMES
Patients with CKD
Relationship between anemia and LVH in patients with
reduced glomerular filtration rate. In a cross-sectional
study of 175 patients attending a kidney disease clinic,
Levin et al [5] evaluated the relationship of hemoglobin
level to echocardiographic findings. The population con-
sisted of 115 men and 60 women with mean age of 51
(range, 20-82). Mean creatinine clearance (Ccr) was 25.5
mL/min, and LVH was present in 38.9% of the popula-
tion. The authors demonstrated that anemia and systolic
blood pressure were the most important modifiable risk
factors associated with the presence of LVH. In multiple
logistic regression analysis each 1g/dL decrease in hemo-
globin was associated with a 6% increase risk of LVH
(P  0.0062). Similar results have been noted in other
studies [26].
Results of longitudinal studies have also demonstrated
an association between hemoglobin and left ventricular
parameters. For example, Levin et al [27] evaluated fac-
tors associated with LV growth (LVG) in a prospective
study of 246 patients with echocardiograms at baseline
and 12 month follow-up. The overall prevalence of LVH
at baseline was 36%. Left ventricular growth, defined
by an increase in left ventricular mass index (LVMI) of
20% or20 g/m2 from baseline to 12 months, occurred
in 25% of the population. Multivariable regression analy-
sis demonstrated a 1.32 increased odds of LVG for each
0.5 g/dL decrease in hemoglobin (P 0.004). Combined,
the results of both of these studies suggest that the pres-
ence of anemia may be a risk factor for LVG and devel-
opment of LVH early in the course of CKD.
Treatment of anemia in patients with reduced glomeru-
lar filtration rate. There have been a number of small
non-randomized studies that have demonstrated im-
provement of cardiac parameters with correction of ane-
mia in patients in the earlier stages of CKD [28, 29].
Portoles et al [28] studied 11 patients with reduced GFR
who received recombinant human erythropoietin for a
6-month period. The hemoglobin increased from 9.0
g/dL to 11.7 g/dL, and there was a trend toward de-
creased LV thickness and a significant decrease in LVMI
(178 g/m2 to 147 g/m2) following treatment. Similarly,
Hayashi et al [29] studied 9 patients with reduced glomer-
ular filtration rate (GFR), with a mean hematocrit (Hct)
of 23.6% and mean LVMI of 140.6 g/m2 at baseline.
These patients were initially partially treated to a goal
Hct of 30% and subsequently to a goal Hct of 40%.
Left ventricular mass index decreased to 126.9 g/m2 after
partial correction of the anemia (Hct, 32%), and to 111.2
g/m2 after full correction of the anemia (Hct, 39%) (P 
0.0001). Finally, randomized trials have demonstrated
significant beneficial cardiovascular effects in terms of
exercise capacity after treatment of anemia [30, 31].
Of interest are 2 ongoing studies. The first is the Cor-
rection of Hemoglobin and Outcomes in Renal Insuffi-
ciency (CHOIR) Study, which randomized 2000 patients
with a baseline hemoglobin of 10.5 to 11 g/dL to a target
hemoglobin of 13 to 13.5 g/dL with the use of recombi-
nant human erythropoietin versus placebo. The primary
outcome is a composite of all-cause mortality, myocar-
dial infarction, stroke, and hospitalization for congestive
heart failure. The second is the Cardiovascular Reduc-
tion by Early Anemia Treatment with Epoetin Beta
(CREATE) Study, which randomized patients to imme-
diate treatment with epoetin beta to a target hemoglobin
of 13 to 15 g/dL, or to late treatment with a target hemo-
globin of 10.5 to 11.5 g/dL, once their hemoglobin levels
have fallen below 10.5 g/dL. The primary outcome is
time to first cardiovascular event.
Relationship between anemia and CVD outcomes in
dialysis patients. Decreased hemoglobin levels have
been associated with a higher risk for CVD events in
dialysis patients. For example, in a cohort of 432 dialysis
patients followed for an average of 41 months, each g/dL
lower hemoglobin was associated with a 1.28 (P 0.018),
1.20 (P  0.046), and 1.14 (P  0.024) adjusted risk of
de novo and recurrent congestive failure, as well as all-
cause mortality, respectively [32]. More recently, Collins
et al [33] studied a cohort of 67,000 United States
Renal Data System hemodialysis patients and assessed
the effect of baseline Hct on the risks of cardiac mortality
at 1 year [33]. In multivariable analysis, they demon-
strated that for patients with Hct values of36%, cardiac
mortality rates were not different when compared with
patients with hematocrit values of 33% to 36%. Patients
with Hct 30% or 30% to 33% were found to have a
higher risk of cardiac death than patients with Hct 33%
to 36% [relative risk (RR) of 1.57 and 1.25, respectively;
(P  0.001 for both)].
Treatment of anemia in dialysis patients. Uncontrolled
studies have suggested that treatment of anemia is associ-
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ated with reduction in left ventricular mass and favorable
outcomes, such as decreased all-cause and CVD mortal-
ity in dialysis patients [34]. Similarly, treatment of ane-
mia from a Hct of 25% to 34% has been shown to
decrease exercise-induced myocardial ischemia, diag-
nosed by EKG monitoring [35].
The results from randomized controlled trials have,
however, been less conclusive. The Normal Hematocrit
Trial enrolled 1200 patients with IHD or congestive
heart failure who were randomized to a Hct goal of
either 30% or 42%. The primary end points were time
to first myocardial infarction or death. Patients random-
ized to the higher Hct group showed a trend toward
increased mortality (though not significant) compared
to patients in the lower Hct group. The exact explanation
for these results remains unknown although potential
reasons included increased access thrombosis in the
higher Hct target, as well as increased iron use in the
higher Hct group [36]. The Canadian Normalization of
Hemoglobin Trial randomized a total of 146 patients
with either asymptomatic concentric LVH or LV dilata-
tion to receive doses of recombinant human erythropoie-
tin designed to achieve a target hemoglobin (Hb) level
of either 10 or 13 g/dL. Results showed that in the con-
centric LVH group and in the LV dilatation group, the
changes in LVMI and LV volume index, respectively,
were similar at both target Hb concentrations. However,
patients with concentric LVH were less likely to develop
progressive LV dilatation if they were randomized to
the high Hb target [37].
Results are now being awaited from a larger ongoing
controlled trial in 544 asymptomatic patients with con-
centric LVH and normal LV cavity volume who are
being randomized to a target Hb of 14 g/dL versus 10
to 11 g/dL. The primary study outcome is percent change
in LV cavity volume and secondary outcomes, is percent
change in LV mass.
These trials suggest that, although there may be some
benefit to treatment of anemia in hemodialysis patients
prior to development of clinical CVD, additional trials
should be conducted in the earlier stages of CKD to
evaluate whether many of the cardiac changes that occur
as GFR declines can be prevented.
Patients with heart failure
Prevalence of anemia in heart failure. The prevalence
of anemia is high in patients with heart failure, increasing
as the severity of the heart failure worsens [38–40]. For
example, Silverberg [40] demonstrated that the preva-
lence of anemia (Hb 12 g/dL) was 9.1% and 19.2%
in patients with New York Heart Association (NYHA)
functional class I or II, respectively, while it was as high
as 79.1% in patients with NYHA functional class IV.
Relationship between anemia and outcomes. Several
studies have now demonstrated that the presence of ane-
mia is an independent risk factor for outcomes in patients
with heart failure. For example, in the Studies of Left
Ventricular Dysfunction (SOLVD), each 1% lower Hct
at baseline was associated with a 3% increase risk in all-
cause mortality in multivariable analysis [39].
Similar findings were noted in a study by Horwich et
al [41], who demonstrated an inverse association be-
tween Hb level and mortality in a study of 1061 patients
with advanced heart failure (NYHA functional class III
or IV and LVEF 40%). In multivariable analysis, each
1 g/dL lower Hb was associated with a relative risk of
1.13 (CI, 1.045–1.22) for all-cause mortality [41].
Treatment of anemia in heart failure. In an uncon-
trolled study, Silverberg et al [40] used a combination
of subcutaneous erythropoietin and intravenous iron to
correct anemia in 26 patients with persistent, severe heart
failure. Treatment resulted in improvements in mean Hb
from 10.2 to 12.1 g/dL (P  0.001), and a decrease in
mean NYHA functional class from 3.7 to 2.7. In addition,
the dose of diuretics and the number of hospitalizations
decreased.
In a controlled trial, Silverberg et al [42] randomized
32 patients with moderate to severe heart failure and
Hb levels of 10.0 to 11.5 g/dL, to a target Hb of 12.5
g/dL versus placebo. Intravenous iron and erythropoietin
were used in the treatment group to achieve the Hb goal.
The treatment group showed an improvement in NYHA
functional class by 42%, in contrast to patients with un-
treated anemia, who showed a decline in NYHA class.
There was also a reduction in the need for oral and
intravenous diuretics, as well as hospitalizations in the
treatment compared with the placebo group.
Finally, Mancini et al [43] have studied the effect of
treatment of anemia on exercise performance in patients
with heart failure. Twenty-six patients with anemia and
heart failure were randomized to receive erythropoietin
or placebo for 3 months. Results revealed that patients
in the treatment group had increased peak oxygen con-
sumption and exercise capacity in comparison with the
placebo group.
Patients with coronary artery disease
The frequency and impact of reduced Hct was investi-
gated in a retrospective analysis of 78,974 Medicare ben-
eficiaries 65 years or older who were hospitalized with
acute myocardial infarction [44]. The authors noted that
patients with lower Hct values on admission had higher
30-day mortality rates (Fig. 2). Furthermore, blood trans-
fusion was associated with a reduction in 30-day mortal-
ity among patients whose Hct on admission ranged from
5.0% to 24.0% (adjusted odds ratio, 0.22; 95% CI, 0.11–
0.45) to 30.1% to 33.0% (adjusted odds ratio, 0.69; 95%
CI, 0.53–0.89). The authors concluded that transfusion
might improve outcomes in elderly patients who are ane-
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Fig. 2. Kaplan-Meier 30-day survival curves
according to hematocrit (Hct) category. Re-
produced with permission from reference [44].
mic and who have suffered an acute myocardial in-
farction [44].
However, not all studies are consistent with this find-
ing. A recent study examined the association of anemia
with 1-year mortality among 30,341 patients hospitalized
with acute myocardial infarction in 1986 (prethrombo-
lytic era, N  15,584) and 1996 (thrombolytic era, N 
14,757). In unadjusted analyses, a higher mortality was
observed among patients with acute myocardial in-
farction and anemia. However, after adjustment for de-
mographics, severity of CVD, and other comorbid condi-
tions there was no difference in the anemic group
compared with the non-anemic group [45].
To our knowledge there are no randomized controlled
trials that have evaluated the effect of treatment of ane-
mia in patients with IHD.
Patients in the general population
Shape of relationship between level of hematocrit and
CVD outcomes. Until this point, we have focused pri-
marily on anemia as a risk factor for CVD outcomes.
However, there are potential reasons to suspect that a
high Hct may also be harmful to the heart and blood
vessels; therefore, the demonstration of non-linear rela-
tionships between level of Hct and CVD outcomes may
not be unexpected. Although a few [abstract; Anker SD
et al: ESC Congress, September 2, 2002], but not all
[46, 47] studies in heart failure have also suggested a
J/U-shaped relation between level of Hct and CVD, this
relationship has been better appreciated in the general
population [48].
Potential adverse effects of high hematocrit on CVD.
The exact mechanism why a higher Hct may be a risk
factor for CVD is not clear. First, the association between
elevated Hct and CVD may reflect confounding from
lung disease. That is, chronic obstructive pulmonary dis-
ease, a risk factor for CVD outcomes, may induce hypo-
xemia and, thereby, stimulation of erythropoiesis [49].
However, in many studies it appears that an elevated Hct
remains an independent risk factor for CVD outcomes,
despite adjustment for potential confounding risk factors
[50]. Second, a higher Hct may lead to increased blood
viscosity and, thereby, increased peripheral resistance
and potentially LVH (Fig. 1) [51]. Third, increases in
Hct may lead to red blood cell aggregation [52], platelet
activation, adhesion and aggregation, and, therefore, in-
crease the risk of thrombus formation [53].
In the following paragraphs we discuss a few of the
large epidemiologic studies in which the relationship of
Hct to CVD outcomes has been evaluated (Table 1).
The Framingham Study. The relationship between
baseline Hct and the risk of CVD morbidity and mortal-
ity over a period of 34 years of follow-up was assessed
in 5209 men and women in the Framingham Study. In
women aged 35 to 64, a non-linear relationship was noted
between level of Hct and IHD mortality. Women with
a Hct 45% or a Hct 40% were both at significantly
increased risk compared with those with an Hct of 42%
to 43%, after adjustment for CVD risk factors. In women
over the age of 65, only a Hct less than 39% was signifi-
cantly associated with an increased risk of IHD mortality.
In men, no association was found between level of Hct
and IHD mortality. However, men aged 35 to 64 ap-
peared to be at increased risk for angina pectoris with
a high Hct [48].
Puerto Rico Health Program. The Puerto Rico Heart
Health Program was a prospective study of IHD in 2555
rural and 6151 urban men aged 45 to 64 years [54].
Subjects were followed for 8 1/4 years. A higher Hct was
associated with an increased risk of myocardial in-
farction, coronary insufficiency, and IHD mortality, for
those living in urban areas and for those aged 55 to
64 years in rural areas. In multivariable analyses the
relationship remained significant only for urban men
(RR, 1.5 for every 10% increase in Hct).
The Honolulu Heart Program. The relationship be-
Pereira and Sarnak: Anemia and cardiovascular disease S-37
Table 1. Effect of high or low Hct on CVD outcomes in the general population
Effect of low Effect of high
Name of study Author, year Definition of CVD Inclusion N Hct on CVDa Hct on CVDb
Puerto Rico Heart Health Program Morbidity and mortality secondary
Sorlie, 1980 to IHD Urban men 6151  
Rural men 2555  
The Honolulu Heart Program Morbidity and mortality secondary
Carter, 1982 to IHD Men 8006  
Oslo Ischemic Study Erikssen, 1993 CVD mortality Men 2014  
The Framingham Study Gagnon, 1994 Morbidity and mortality secondary Men and women 5209 ND ND
to CVDg Men 35–64 ND  c
Men 64 ND  e
Women 35–64 ND d f
Women 64 ND f 
NHANES II Study Brown, 2001 Mortality secondary to IHD Men 4213  
Women 4683  
ARIC Study Sarnak, 2002 Morbidity and mortality secondary Men and women 14410  ND
to IHD Men 6267  ND
Women 8143  ND
Abbreviations are: IHD, ischemic heart disease; CVD, cardiovascular disease; NHANES, National Health and Nutrition Examination Survey; Hct, hematocrit.
, statistically significant association present; , no association detected; ND, no data available.
a,bEffect of Hct on CVD outcomes in multivariable analyses
cSignificant association for angina pectoris only
dSignificant association for IHD mortality only
eSignificant association for CVD mortality only
fSignificant association for both CVD morbidity and mortality
gCVD morbidity in Framingham Study defined as either IHD (including angina pectoris), intermittent claudication, congestive heart failure, stroke, or transient
ischemic attack. CVD mortality in Framingham Study defined as death from diseases of the heart or blood vessels, including the above causes.
tween baseline Hct and IHD was assessed in 8000 Japa-
nese men who were followed for a mean of 10 years in
the Honolulu Heart Program. A higher Hct at baseline
was noted in those who died of IHD. However, after
adjustment for other CVD risk factors, this association
did not persist [55].
Oslo Ischemic Study. The relationship of Hct to CVD
mortality was assessed in 488 healthy Norwegian men
who were followed for a period of 16 years. After adjust-
ment for other CVD risk factors, each 2 standard devia-
tions higher Hct at baseline was associated with a RR
for CVD mortality of 2.9 at 10 years and 1.9 at 16 years
(P  0.005) [56].
NHANES II Mortality Study. All-cause and cause-
specific mortality were obtained from death certificates
16.8 years after 8896 adults aged 30 to 75 were enrolled in
the Second National Health and Nutrition Examination
survey (NHANES II) Mortality Study [57]. The crude
IHD mortality rate per 10,000 population among men
was found to be 42.6, 31.9, and 46.3 among those with
Hct in the lower (19% to 43%), middle (43.2% to
45.2%), and upper (45.5% to 61.75%) tertiles, respec-
tively (Fig. 3). The corresponding crude IHD mortality
rates among women were 12.6, 18.6, and 22.7 among
those with Hct in the lower (14.5% to 39.0%), middle
(39.2% to 41.5%), and upper (41.7% to 58.5%) tertiles
(Fig. 3). After adjustment for other CVD risk factors,
there was no association between Hct and IHD mortality
among men. In women, subjects in the upper tertile
showed a trend toward increased IHD mortality com-
pared to those in the lower tertile (RR, 1.3, 95% CI 0.9–
1.9).
Fig. 3. Unadjusted mortality rate per 10,000 population for coronary
heart disease and diseases of the heart among (A ) men and (B ) women
aged 30 to 75 years. Reproduced with permission from reference [57].
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Fig. 4. Kaplan-Meier survival analysis for cardiovascular disease
(CVD) in men and women stratified by presence versus absence of
anemia. Log-rank statistics were significant (P 0.03 for men, P 0.04
for women) for differences between anemic and non-anemic subjects.
Dotted line represents anemia; solid line represents nonanemia. Repro-
duced with permission from reference [58].
Atherosclerosis Risk in Communities Study (ARIC).
The ARIC study is a prospective cohort study of athero-
sclerosis and its risk factors in 4 United States communi-
ties. Anemia was defined using World Health Organiza-
tion criteria, namely a Hb level 12 g/dL in women and
13 g/dL in men. A total of 14,410 subjects without
CVD at baseline had Hb levels measured. Three hundred
men (4.8%) and 1058 women (13.0%) were anemic at
baseline. The presence of anemia was associated with
CVD outcomes in men and women (Fig. 4). Anemia was
also independently associated with an increased risk of
CVD in the entire cohort [hazards ratio (HR), 1.41, 95%
CI 1.01-1.95]. In subgroup analyses, the hazard ratios
were in the same direction, although not statistically
significant in all cases [58]. For example, the HR (95%
CI) was 1.33 (0.85–2.08), 1.71 (1.01–2.89), 1.18 (0.74–1.88),
and 1.63 (1.03–2.59) in men, women, African Americans,
and Whites, respectively.
Interpretation of the results. These studies unfortu-
nately do not provide us with any definitive answers
regarding the relationship of anemia and level of Hct to
CVD. It appears that the relationship between Hct and
CVD may vary depending on the gender, the age group
being studied, the population being studied, and the de-
gree of anemia being evaluated. Of note, none of the
studies provide us detailed data of the causes of low
Hct. This is particularly important in relation to the iron
deficiency hypothesis presented above.
The analysis of the ARIC cohort was unique in that
it evaluated anemia rather than tertiles or quintiles of
Hct. In this respect it is important to note that only
approximately 10% of subjects had anemia. Therefore,
it is possible that only the lowest decile of Hct is associ-
ated with CVD outcomes.
CONCLUSION
Anemia appears to be an independent risk factor for
surrogates of CVD, such as LVH, and with clinical CVD
outcomes in patients with CKD or heart failure. In these
2 populations, randomized controlled trials are needed
to assess if this is due to a cause-and-effect relationship
and whether treatment of anemia can reduce CVD out-
comes.
In patients with IHD and in subjects in the general
population the relationship between anemia with CVD is
inconclusive. Future observational studies that evaluate
this relationship should attempt to identify both the
cause of the anemia as well as surrogates of CVD. The
reason for the latter is that anemia itself may result in
ventricular remodeling and LVH, while iron deficiency
anemia could theoretically improve endothelial function.
Therefore, the possibility of competing risks may be at
play.
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